Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Gynecology · Uterine Leiomyoma

Medical Management and Symptom Control for Uterine Fibroids

At a Glance

Medical treatment for uterine fibroids mainly controls heavy bleeding, cramps, pain, and anemia rather than removing fibroids. Options include non-hormonal medicines, hormonal IUDs, birth control, and time-limited GnRH antagonists; symptoms may return after stopping.

Medical management of uterine fibroids is primarily focused on symptom control rather than eliminating the fibroids themselves [1][2]. For many, these treatments serve as a “bridge” to menopause or a temporary measure to improve health—such as correcting anemia—before a planned surgery [3][4].

If you have fibroids but no symptoms, your doctor may recommend expectant management (watchful waiting) [1]. Many asymptomatic patients need no treatment, and follow-up is driven by changes in symptoms rather than universal serial imaging. New heavy bleeding, anemia, rapidly increasing bulk symptoms, or postmenopausal growth should prompt reassessment.

Non-Hormonal and Targeted Options

For those primarily struggling with heavy periods, non-hormonal treatments can be used during your period to reduce blood loss. Important: Do not start these without a clinician or pharmacist review, as they have safety contraindications.

  • Tranexamic Acid: This is a non-hormonal medication taken during your period that helps blood clot more effectively in the uterine lining [5]. Before use, this requires an assessment of your thromboembolic (blood clot) risk [6].
  • NSAIDs: Medications like ibuprofen or naproxen can help reduce menstrual cramps and may slightly decrease blood flow. However, they may be unsafe if you have kidney disease, ulcer disease, or take anticoagulants [2][5].
  • Iron Supplementation: If heavy bleeding has led to iron-deficiency anemia, taking iron is a critical part of your medical plan to restore energy levels and prepare your body for any future procedures [6][3].

Hormonal Options: IUDs and Birth Control

Hormonal treatments work by thinning the uterine lining, which makes periods lighter. It is important to know that estrogen-containing options have clot and cardiovascular contraindications that must be evaluated.

  • Hormonal IUD (LNG-IUS): A small device placed in the uterus that releases progestin. It is very effective at reducing bleeding, though it may be more likely to be expelled if your fibroids significantly distort the shape of your uterine cavity [7][8].
  • Combined Oral Contraceptives: Birth control pills containing both estrogen and progestin can help regulate periods and reduce flow, though they generally do not shrink the size of the fibroids [9][7].

Advanced Medical Therapy: GnRH Antagonists

A newer class of oral medications, including elagolix and relugolix, offers a more powerful way to manage symptoms by directly suppressing the hormones that feed fibroid growth [10][11].

How They Work

These drugs block the GnRH receptor in the brain, which tells the ovaries to stop producing estrogen and progesterone [12]. This creates a temporary, reversible state similar to menopause, which can stop periods entirely and may slightly shrink the fibroids [11][13].

  • Efficacy: In clinical trials, about 70–76% of women saw a significant reduction in bleeding while taking these medications [10][11].
  • Add-Back Therapy: Because very low estrogen levels can cause hot flashes and bone thinning, these drugs are prescribed with add-back therapy—a tiny dose of estrogen and progestin [14]. The exact approved product, add-back regimen, and contraindications depend on the specific medication [15][14].

Safety and Limits

  • Safety Limits: Even with add-back therapy, there are limits on how long you can take these medications. In the U.S., elagolix combination therapy is labeled for up to 24 months, while relugolix combination therapy has demonstrated efficacy through 2 years [16]. Your clinician will monitor bone density, liver function, and cardiovascular factors.
  • Symptom Return: These medications do not cure fibroids. Once you stop taking them, heavy menstrual bleeding and symptoms commonly return [17][18].
  • Contraception: While these drugs suppress ovulation, they are not guaranteed birth control. You must use non-hormonal contraception (like condoms) while taking them [19].

Important Considerations for Fertility

It is important to understand that medical therapy is not a treatment for infertility caused by fibroids [20]. Most hormonal treatments and GnRH antagonists work by stopping ovulation or making the uterine lining less receptive to an embryo [20][21]. If your goal is to get pregnant, medical therapy may be used briefly to improve your health (like treating anemia) before surgery, but it is not a stand-alone solution for conceiving [20][22].

Common questions in this guide

Which medicines can reduce heavy bleeding from uterine fibroids?
Options include tranexamic acid during menstrual periods, NSAIDs such as ibuprofen or naproxen, hormonal IUDs, combined birth-control pills, and GnRH antagonist medicines such as elagolix or relugolix. The safest choice depends on your bleeding pattern, fibroid location, other health conditions, medications, and pregnancy plans.
Do medications for uterine fibroids remove or permanently shrink them?
Most medical treatments control bleeding or pain rather than remove fibroids. GnRH antagonists may slightly shrink fibroids while you take them, but symptoms commonly return after the medicine is stopped, so they are not a permanent cure.
What should I know before taking elagolix or relugolix for fibroids?
These medicines lower the ovarian hormones that contribute to fibroid symptoms and can temporarily stop periods, creating a menopause-like state. They are usually prescribed with add-back hormones to reduce hot flashes and bone loss, and treatment duration, bone density, liver function, and cardiovascular risks need review with a clinician.
Can fibroid medicines help me get pregnant?
Medical treatment is generally not a stand-alone treatment for infertility caused by fibroids. Many hormonal treatments and GnRH antagonists stop ovulation or make the uterine lining less receptive to an embryo, although short-term treatment may help correct anemia or prepare for surgery.
Is a hormonal IUD a good option for fibroid-related heavy bleeding?
A hormonal IUD can substantially reduce menstrual bleeding by releasing progestin that thins the uterine lining. It may be more likely to come out if fibroids significantly distort the inside shape of the uterus, so a clinician should assess whether placement is suitable.
When should my fibroid treatment plan be reassessed?
Contact your clinician about new or worsening heavy bleeding, symptoms of anemia such as extreme fatigue or palpitations, rapidly increasing pressure or bulk symptoms, or fibroid growth after menopause. These changes may require a new evaluation rather than simply continuing the same medicine.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my fibroid location and size, which medical option is most likely to reduce my heavy bleeding?
  2. 2.If we consider elagolix or relugolix, what is the approved duration limit, and how will we monitor my bone density over time?
  3. 3.Is my current iron-deficiency anemia severe enough that I need iron infusions alongside these medications?
  4. 4.Since I am not trying to get pregnant right now, would an IUD or a GnRH antagonist be a better choice for long-term symptom management?
  5. 5.What changes in my symptoms should prompt us to reassess my treatment plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Guideline No. 461: The Management of Uterine Fibroids.

    Chen I, Kives S, Randle E, et al.

    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2025; (47(8)):102970 doi:10.1016/j.jogc.2025.102970.

    PMID: 40562356
  2. 2

    Uterine Fibroids: Diagnosis and Treatment.

    De La Cruz MS, Buchanan EM

    American family physician 2017; (95(2)):100-107.

    PMID: 28084714
  3. 3

    Medical therapy for fibroids: An overview.

    Sinai Talaulikar V

    Best practice & research. Clinical obstetrics & gynaecology 2018; (46()):48-56 doi:10.1016/j.bpobgyn.2017.09.007.

    PMID: 29066045
  4. 4

    Tailoring the Diagnostic Pathway for Medical and Surgical Treatment of Uterine Fibroids: A Narrative Review.

    Centini G, Cannoni A, Ginetti A, et al.

    Diagnostics (Basel, Switzerland) 2024; (14(18)) doi:10.3390/diagnostics14182046.

    PMID: 39335725
  5. 5

    Role of Medical Management for Uterine Leiomyomas.

    Kashani BN, Centini G, Morelli SS, et al.

    Best practice & research. Clinical obstetrics & gynaecology 2016; (34()):85-103.

    PMID: 26796059
  6. 6

    The modern management of uterine fibroids-related abnormal uterine bleeding.

    Vannuccini S, Petraglia F, Carmona F, et al.

    Fertility and sterility 2024; (122(1)):20-30 doi:10.1016/j.fertnstert.2024.04.041.

    PMID: 38723935
  7. 7

    Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy).

    Sangkomkamhang US, Lumbiganon P, Pattanittum P

    The Cochrane database of systematic reviews 2020; (11()):CD008994 doi:10.1002/14651858.CD008994.pub3.

    PMID: 33226133
  8. 8

    The medical management of abnormal uterine bleeding in reproductive-aged women.

    Bradley LD, Gueye NA

    American journal of obstetrics and gynecology 2016; (214(1)):31-44.

    PMID: 26254516
  9. 9

    Current medical treatment of uterine fibroids.

    Sohn GS, Cho S, Kim YM, et al.

    Obstetrics & gynecology science 2018; (61(2)):192-201 doi:10.5468/ogs.2018.61.2.192.

    PMID: 29564309
  10. 10

    Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.

    Schlaff WD, Ackerman RT, Al-Hendy A, et al.

    The New England journal of medicine 2020; (382(4)):328-340 doi:10.1056/NEJMoa1904351.

    PMID: 31971678
  11. 11

    Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.

    Al-Hendy A, Lukes AS, Poindexter AN, et al.

    The New England journal of medicine 2021; (384(7)):630-642 doi:10.1056/NEJMoa2008283.

    PMID: 33596357
  12. 12

    Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.

    Al-Hendy A, Bradley L, Owens CD, et al.

    American journal of obstetrics and gynecology 2021; (224(1)):72.e1-72.e50 doi:10.1016/j.ajog.2020.07.032.

    PMID: 32702363
  13. 13

    Uterine fibroid-related infertility: mechanisms and management.

    Donnez J, Taylor HS, Marcellin L, Dolmans MM

    Fertility and sterility 2024; (122(1)):31-39 doi:10.1016/j.fertnstert.2024.02.049.

    PMID: 38453041
  14. 14

    Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.

    Simon JA, Al-Hendy A, Archer DF, et al.

    Obstetrics and gynecology 2020; (135(6)):1313-1326 doi:10.1097/AOG.0000000000003869.

    PMID: 32459423
  15. 15

    Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas.

    Neblett MF, Stewart EA

    Obstetrics and gynecology 2023; (141(5)):901-910 doi:10.1097/AOG.0000000000005145.

    PMID: 37103532
  16. 16

    Interdisciplinary model-informed drug development for extending duration of elagolix treatment in patients with uterine fibroids.

    Beck D, Winzenborg I, Gao W, et al.

    British journal of clinical pharmacology 2022; (88(12)):5257-5268 doi:10.1111/bcp.15440.

    PMID: 35695781
  17. 17

    LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.

    Al-Hendy A, Venturella R, Arjona Ferreira JC, et al.

    American journal of obstetrics and gynecology 2023; (229(6)):662.e1-662.e25 doi:10.1016/j.ajog.2023.08.030.

    PMID: 37666383
  18. 18

    Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.

    Osuga Y, Enya K, Kudou K, et al.

    Obstetrics and gynecology 2019; (133(3)):423-433 doi:10.1097/AOG.0000000000003141.

    PMID: 30741797
  19. 19

    Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women.

    Archer DF, Ng J, Chwalisz K, et al.

    The Journal of clinical endocrinology and metabolism 2020; (105(3)) doi:10.1210/clinem/dgz086.

    PMID: 31650182
  20. 20

    The management of uterine fibroids in women with otherwise unexplained infertility.

    Carranza-Mamane B, Havelock J, Hemmings R, et al.

    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2015; (37(3)):277-285 doi:10.1016/S1701-2163(15)30318-2.

    PMID: 26001875
  21. 21

    The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications.

    Barretta M, Vignali M, La Marca A, Grandi G

    Expert opinion on drug metabolism & toxicology 2024; 1-13 doi:10.1080/17425255.2024.2441981.

    PMID: 39666595
  22. 22

    Literature Review on the Role of Uterine Fibroids in Endometrial Function.

    Ikhena DE, Bulun SE

    Reproductive sciences (Thousand Oaks, Calif.) 2018; (25(5)):635-643 doi:10.1177/1933719117725827.

    PMID: 28826369

This page is for informational purposes only and does not constitute medical advice. Talk with your gynecologist or pharmacist before starting treatment, especially if you have anemia, clotting risks, or fertility plans.

Get notified when new evidence is published on uterine corpus leiomyoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.